{
    "hands_on_practices": [
        {
            "introduction": "The diagnosis and monitoring of Eosinophilic Esophagitis (EoE) rely heavily on visual assessment during endoscopy. To move from subjective description to objective measurement, clinicians use standardized tools like the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS). This practice will help you master the EREFS system by translating a descriptive endoscopy report into a quantitative score, a crucial skill for tracking disease activity and communicating findings consistently. ",
            "id": "4832504",
            "problem": "A patient with suspected Eosinophilic Esophagitis (EoE) undergoes esophagogastroduodenoscopy. The endoscopy report documents: decreased clarity of mucosal vascular markings throughout the esophagus, exactly two distinct fixed circumferential rings, scattered punctate white exudates without confluent plaques, and longitudinal furrows. No focal narrowing or small-caliber esophagus is noted, and there is no report of resistance to passage of a standard adult diagnostic upper endoscope.\n\nUse the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), a standardized classification that grades the following features based on endoscopic appearance:\n- Edema: score $0$ if absent (normal distinct vascularity), score $1$ if present (decreased or absent vascular markings).\n- Rings: score $0$ if none, score $1$ if mild (subtle, non-fixed circumferential ridges), score $2$ if moderate (distinct fixed rings), score $3$ if severe (small-caliber esophagus).\n- Exudates: score $0$ if none, score $1$ if mild (discrete specks involving less than $0.10$ of the esophageal mucosal surface area), score $2$ if severe (plaques involving at least $0.10$ of the esophageal mucosal surface area).\n- Furrows: score $0$ if absent, score $1$ if present.\n- Stricture: score $0$ if absent, score $1$ if present.\n\nStarting from these definitions and the pathophysiological correlation that mucosal edema in EoE manifests endoscopically as decreased vascular visibility, translate each reported finding into its EREFS component grade and compute the total EREFS by summing the component scores. Express your final result as an exact integer without units.",
            "solution": "The problem is first assessed for validity.\n\n**Step 1: Extract Givens**\nThe provided data from the problem statement are:\n- Endoscopic findings in a patient with suspected Eosinophilic Esophagitis (EoE):\n    - \"decreased clarity of mucosal vascular markings throughout the esophagus\"\n    - \"exactly two distinct fixed circumferential rings\"\n    - \"scattered punctate white exudates without confluent plaques\"\n    - \"longitudinal furrows\"\n    - \"No focal narrowing or small-caliber esophagus is noted\"\n    - \"no report of resistance to passage of a standard adult diagnostic upper endoscope\"\n- The Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) system definitions:\n    - Edema ($S_{edema}$): $0$ = absent (normal distinct vascularity); $1$ = present (decreased or absent vascular markings).\n    - Rings ($S_{rings}$): $0$ = none; $1$ = mild (subtle, non-fixed ridges); $2$ = moderate (distinct fixed rings); $3$ = severe (small-caliber esophagus).\n    - Exudates ($S_{exudates}$): $0$ = none; $1$ = mild (discrete specks, $< 0.10$ surface area); $2$ = severe (plaques, $\\ge 0.10$ surface area).\n    - Furrows ($S_{furrows}$): $0$ = absent; $1$ = present.\n    - Stricture ($S_{stricture}$): $0$ = absent; $1$ = present.\n- The task is to compute the total EREFS, which is the sum of the individual component scores.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding:** The problem is scientifically grounded. Eosinophilic Esophagitis is a recognized medical condition, and the EREFS is a validated, widely used scoring system in gastroenterology for standardizing the endoscopic evaluation of EoE. The described findings and their correlation with the scoring components are factually correct and based on established clinical principles.\n- **Well-Posedness:** The problem is well-posed. It provides a complete set of clinical observations and a well-defined, discrete scoring rubric. The instructions to map the findings to the scores and sum them lead to a unique and meaningful integer result.\n- **Objectivity:** The problem is objective. The provided endoscopic descriptions and the EREFS definitions are clear and precise, allowing for a deterministic mapping without subjective interpretation.\n- **Consistency:** The given information is internally consistent. For example, the finding of \"no focal narrowing or small-caliber esophagus\" is consistent with the absence of a stricture and the absence of the most severe form of rings.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid as it is scientifically sound, well-posed, objective, and internally consistent. A solution will be formulated.\n\n**Solution Formulation**\nThe total Eosinophilic Esophagitis Endoscopic Reference Score ($S_{total}$) is calculated by summing the scores of its five components: Edema ($S_{edema}$), Rings ($S_{rings}$), Exudates ($S_{exudates}$), Furrows ($S_{furrows}$), and Stricture ($S_{stricture}$). Each component is scored by translating the endoscopic report's findings into the provided EREFS definitions.\n\n1.  **Edema Score ($S_{edema}$):**\n    The report states there is \"decreased clarity of mucosal vascular markings throughout the esophagus\". According to the EREFS definition, edema is scored as $1$ if present, which is indicated by \"decreased or absent vascular markings\".\n    Therefore, $S_{edema} = 1$.\n\n2.  **Rings Score ($S_{rings}$):**\n    The report documents \"exactly two distinct fixed circumferential rings\". The EREFS definition for a score of $2$ is \"moderate (distinct fixed rings)\". The absence of a \"small-caliber esophagus\" confirms the score is not $3$.\n    Therefore, $S_{rings} = 2$.\n\n3.  **Exudates Score ($S_{exudates}$):**\n    The finding is \"scattered punctate white exudates without confluent plaques\". This description aligns with the EREFS definition for a score of $1$, which is \"mild (discrete specks involving less than $0.10$ of the esophageal mucosal surface area)\". The term \"punctate\" corresponds to \"discrete specks\", and the absence of \"confluent plaques\" rules out a score of $2$.\n    Therefore, $S_{exudates} = 1$.\n\n4.  **Furrows Score ($S_{furrows}$):**\n    The report explicitly notes the presence of \"longitudinal furrows\". The EREFS definition for a score of $1$ is \"present\".\n    Therefore, $S_{furrows} = 1$.\n\n5.  **Stricture Score ($S_{stricture}$):**\n    The report states, \"No focal narrowing or small-caliber esophagus is noted, and there is no report of resistance to passage of a standard adult diagnostic upper endoscope.\" These observations confirm the absence of a stricture. The EREFS definition for a score of $0$ is \"absent\".\n    Therefore, $S_{stricture} = 0$.\n\n**Total EREFS Calculation:**\nThe total score is the sum of the individual component scores:\n$$S_{total} = S_{edema} + S_{rings} + S_{exudates} + S_{furrows} + S_{stricture}$$\nSubstituting the determined values:\n$$S_{total} = 1 + 2 + 1 + 1 + 0$$\n$$S_{total} = 5$$\nThe total Eosinophilic Esophagitis Endoscopic Reference Score is $5$.",
            "answer": "$$\n\\boxed{5}\n$$"
        },
        {
            "introduction": "Identifying food antigen triggers is a cornerstone of managing many patients with EoE, but the available diagnostic tools are imperfect. This exercise explores the real-world utility of skin prick testing (SPT) by going beyond simple sensitivity and specificity. By applying fundamental principles of biostatistics, you will calculate the test's positive and negative predictive values, providing a much clearer picture of what a test result actually means for your patient. ",
            "id": "4832531",
            "problem": "A subspecialty clinic is evaluating whether to rely on skin prick testing (SPT) to prioritize elimination of suspected food triggers in patients with eosinophilic esophagitis (EoE). Consider a population of patients with suspected EoE in whom the pretest probability that a given tested food is a true trigger is $50\\%$. Assume the SPT has sensitivity $30\\%$ and specificity $80\\%$ for identifying true food triggers as established by a criterion standard (symptom and histologic recurrence on blinded reintroduction after elimination).\n\nStarting only from the fundamental definitions of sensitivity, specificity, and pretest probability (as the disease prevalence in the tested population) and Bayes' theorem for conditional probabilities, compute the positive predictive value and the negative predictive value of the SPT in this setting. Express each as a decimal (unitless) and round to $4$ significant figures.",
            "solution": "The problem is valid as it is scientifically grounded in the principles of biostatistics, well-posed with sufficient information for a unique solution, and stated objectively. We proceed with the solution.\n\nLet us define the following events:\n- $D$: The event that a tested food is a true trigger for eosinophilic esophagitis (EoE).\n- $D^c$: The event that a tested food is not a true trigger for EoE.\n- $T^+$: The event that the skin prick test (SPT) is positive.\n- $T^-$: The event that the skin prick test (SPT) is negative.\n\nFrom the problem statement, we are given the following probabilities, expressed as decimals:\n1.  The pretest probability that a food is a true trigger, which corresponds to the prevalence of the \"disease\" state in the tested population:\n    $$P(D) = 0.50$$\n2.  The sensitivity of the SPT, which is the probability of a positive test given that the food is a true trigger:\n    $$P(T^+ | D) = 0.30$$\n3.  The specificity of the SPT, which is the probability of a negative test given that the food is not a true trigger:\n    $$P(T^- | D^c) = 0.80$$\n\nFrom these given probabilities, we can derive their complementary probabilities:\n- The probability that a food is not a true trigger:\n  $$P(D^c) = 1 - P(D) = 1 - 0.50 = 0.50$$\n- The false negative rate, which is the probability of a negative test given that the food is a true trigger:\n  $$P(T^- | D) = 1 - P(T^+ | D) = 1 - 0.30 = 0.70$$\n- The false positive rate, which is the probability of a positive test given that the food is not a true trigger:\n  $$P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - 0.80 = 0.20$$\n\nWe are tasked with computing the positive predictive value (PPV) and the negative predictive value (NPV). These are defined as follows:\n- PPV: The probability that a food is a true trigger given a positive test result, which is the conditional probability $P(D | T^+)$.\n- NPV: The probability that a food is not a true trigger given a negative test result, which is the conditional probability $P(D^c | T^-)$.\n\nWe will use Bayes' theorem, which states that for any two events $A$ and $B$ with $P(B) > 0$:\n$$P(A | B) = \\frac{P(B | A) P(A)}{P(B)}$$\nThe denominator $P(B)$ can be computed using the law of total probability. For an event $B$ and a partition of the sample space $\\{A_i\\}$, the law states:\n$$P(B) = \\sum_i P(B | A_i) P(A_i)$$\nIn this problem, the sample space is partitioned by the events $\\{D, D^c\\}$.\n\nFirst, we compute the positive predictive value (PPV).\nBy definition, $PPV = P(D | T^+)$. Applying Bayes' theorem:\n$$PPV = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)}$$\nWe must first compute the total probability of a positive test, $P(T^+)$, using the law of total probability:\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\nSubstituting the known and derived values:\n$$P(T^+) = (0.30)(0.50) + (0.20)(0.50)$$\n$$P(T^+) = 0.15 + 0.10 = 0.25$$\nNow, we can substitute this result back into the expression for PPV:\n$$PPV = \\frac{P(T^+ | D) P(D)}{P(T^+)} = \\frac{(0.30)(0.50)}{0.25} = \\frac{0.15}{0.25}$$\n$$PPV = 0.6$$\nAs a decimal rounded to $4$ significant figures, this is $0.6000$.\n\nNext, we compute the negative predictive value (NPV).\nBy definition, $NPV = P(D^c | T^-)$. Applying Bayes' theorem:\n$$NPV = P(D^c | T^-) = \\frac{P(T^- | D^c) P(D^c)}{P(T^-)}$$\nWe must first compute the total probability of a negative test, $P(T^-)$. We can use the law of total probability again:\n$$P(T^-) = P(T^- | D) P(D) + P(T^- | D^c) P(D^c)$$\nSubstituting the known and derived values:\n$$P(T^-) = (0.70)(0.50) + (0.80)(0.50)$$\n$$P(T^-) = 0.35 + 0.40 = 0.75$$\nAs a consistency check, we note that since the test must be either positive or negative, $P(T^-) = 1 - P(T^+) = 1 - 0.25 = 0.75$, which matches our calculation.\nNow, we substitute this result back into the expression for NPV:\n$$NPV = \\frac{P(T^- | D^c) P(D^c)}{P(T^-)} = \\frac{(0.80)(0.50)}{0.75} = \\frac{0.40}{0.75}$$\n$$NPV = \\frac{40}{75} = \\frac{8}{15}$$\nAs a decimal, this is $0.53333...$. Rounding to $4$ significant figures as required gives $0.5333$.\n\nThe positive predictive value is $0.6000$ and the negative predictive value is $0.5333$.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.6000 & 0.5333 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Selecting the optimal therapy for EoE involves a complex trade-off between efficacy, cost, and potential adverse effects. This advanced problem challenges you to use decision analysis, a powerful framework for making rational choices under uncertainty. You will construct a two-stage treatment strategy and calculate the expected cost to identify the most cost-effective approach that meets a desired clinical outcome, simulating a high-level decision-making process common in modern healthcare. ",
            "id": "4832507",
            "problem": "A clinician is managing a patient with eosinophilic esophagitis (EoE) and must select an initial therapy among three evidence-based options, with a plan to escalate to a biologic therapy only if histologic remission is not achieved after the initial course. The goal is to minimize the expected total cost while ensuring that the overall probability of histologic remission meets a predefined threshold. Use the axioms of probability and the definition of expected value to construct and analyze a two-stage decision tree.\n\nDefine the two-stage strategy as follows: choose one initial therapy, reassess histology with endoscopy after $8$ weeks, and if remission has not been achieved, proceed to a single $12$-week course of a biologic, followed by repeat endoscopy. Assume independence between histologic remission and adverse events within and across therapies, and that adverse event costs are incurred only if the corresponding therapy is administered.\n\nInitial therapy options:\n- Proton pump inhibitor (PPI): direct $8$-week therapy cost $=$ $\\$200$, histologic remission probability $=$ $0.42$, adverse event probability $=$ $0.01$, adverse event management cost $=$ $\\$300$.\n- Swallowed topical corticosteroid (STC; budesonide): direct $8$-week therapy cost $=$ $\\$650$, histologic remission probability $=$ $0.65$, adverse event probability $=$ $0.03$, adverse event management cost $=$ $\\$150$.\n- Six-food elimination diet (SFED): direct $8$-week therapy cost $=$ $\\$400$, histologic remission probability $=$ $0.54$, adverse event probability $=$ $0$, adverse event management cost $=$ $\\$0$.\n\nRescue biologic therapy:\n- Dupilumab: direct $12$-week therapy cost $=$ $\\$9{,}600$, histologic remission probability $=$ $0.75$, adverse event probability $=$ $0.02$, adverse event management cost $=$ $\\$500$.\n\nEndoscopy:\n- Each histologic assessment endoscopy costs $\\$1{,}200$ and is performed after the initial $8$-week course and, if rescue therapy is used, after the $12$-week course.\n\nLet the predefined minimum acceptable overall probability of histologic remission be $R_{\\min} = 0.85$. The overall remission probability of a two-stage strategy equals the probability of remission after the initial therapy plus the probability of no remission after the initial therapy multiplied by the probability of remission after the rescue therapy.\n\nFor each choice of initial therapy, derive the expected total cost of the two-stage strategy and determine whether the overall remission probability constraint $R \\geq R_{\\min}$ is satisfied. Among the initial therapy options that satisfy the constraint, identify the strategy with the minimal expected total cost.\n\nExpress the minimal expected total cost in United States dollars (USD) and round your answer to four significant figures.",
            "solution": "The objective is to identify the initial therapy (PPI, STC, or SFED) that minimizes the expected total cost of a two-stage treatment strategy, subject to the constraint that the overall probability of histologic remission is at least $0.85$.\n\nLet $i$ represent the choice of initial therapy. The overall probability of remission, $R_{overall, i}$, is the probability of remission from the initial therapy, $p_i$, plus the probability of failing the initial therapy and then achieving remission with the rescue therapy (dupilumab, denoted by subscript $D$):\n$R_{overall, i} = p_i + (1 - p_i) p_D$\n\nThe expected total cost, $E[C_i]$, is the sum of the expected costs from the initial therapy stage and the rescue therapy stage. The initial stage always includes the therapy cost $C_i$, the first endoscopy cost $C_{endo}$, and the expected cost of an adverse event $q_i C_{AE,i}$. If the initial therapy fails (with probability $1-p_i$), the costs of the rescue stage are incurred. This stage includes the rescue therapy cost $C_D$, a second endoscopy cost $C_{endo}$, and the expected cost of a rescue therapy adverse event $q_D C_{AE,D}$.\n$E[C_i] = (C_i + C_{endo} + q_i C_{AE,i}) + (1-p_i) \\times (C_D + C_{endo} + q_D C_{AE,D})$\n\nThe given values are:\n- $p_{PPI} = 0.42, C_{PPI} = \\$200, q_{PPI} = 0.01, C_{AE,PPI} = \\$300$\n- $p_{STC} = 0.65, C_{STC} = \\$650, q_{STC} = 0.03, C_{AE,STC} = \\$150$\n- $p_{SFED} = 0.54, C_{SFED} = \\$400, q_{SFED} = 0, C_{AE,SFED} = \\$0$\n- $p_D = 0.75, C_D = \\$9600, q_D = 0.02, C_{AE,D} = \\$500$\n- $C_{endo} = \\$1200$\n- $R_{\\min} = 0.85$\n\nFirst, let's calculate the expected cost of the rescue therapy branch, which is constant for all strategies if triggered:\n$E[C_{rescue\\_branch}] = C_D + C_{endo} + q_D C_{AE,D} = \\$9600 + \\$1200 + (0.02 \\times \\$500) = \\$10800 + \\$10 = \\$10810$.\n\nNow, we evaluate each of the three strategies:\n\n**1. Initial Therapy: Proton Pump Inhibitor (PPI)**\n- Overall Remission Probability:\n  $R_{overall, PPI} = p_{PPI} + (1-p_{PPI})p_D = 0.42 + (1-0.42)(0.75) = 0.42 + (0.58)(0.75) = 0.42 + 0.435 = 0.855$.\n  Since $0.855 \\geq 0.85$, this strategy is valid.\n- Expected Total Cost:\n  $E[C_{PPI}] = (C_{PPI} + C_{endo} + q_{PPI}C_{AE,PPI}) + (1-p_{PPI}) \\times E[C_{rescue\\_branch}]$\n  $E[C_{PPI}] = (\\$200 + \\$1200 + 0.01 \\times \\$300) + (0.58) \\times \\$10810$\n  $E[C_{PPI}] = (\\$1403) + \\$6269.80 = \\$7672.80$.\n\n**2. Initial Therapy: Swallowed Topical Corticosteroid (STC)**\n- Overall Remission Probability:\n  $R_{overall, STC} = p_{STC} + (1-p_{STC})p_D = 0.65 + (1-0.65)(0.75) = 0.65 + (0.35)(0.75) = 0.65 + 0.2625 = 0.9125$.\n  Since $0.9125 \\geq 0.85$, this strategy is valid.\n- Expected Total Cost:\n  $E[C_{STC}] = (C_{STC} + C_{endo} + q_{STC}C_{AE,STC}) + (1-p_{STC}) \\times E[C_{rescue\\_branch}]$\n  $E[C_{STC}] = (\\$650 + \\$1200 + 0.03 \\times \\$150) + (0.35) \\times \\$10810$\n  $E[C_{STC}] = (\\$1850 + \\$4.50) + \\$3783.50 = \\$1854.50 + \\$3783.50 = \\$5638$.\n\n**3. Initial Therapy: Six-Food Elimination Diet (SFED)**\n- Overall Remission Probability:\n  $R_{overall, SFED} = p_{SFED} + (1-p_{SFED})p_D = 0.54 + (1-0.54)(0.75) = 0.54 + (0.46)(0.75) = 0.54 + 0.345 = 0.885$.\n  Since $0.885 \\geq 0.85$, this strategy is valid.\n- Expected Total Cost:\n  $E[C_{SFED}] = (C_{SFED} + C_{endo} + q_{SFED}C_{AE,SFED}) + (1-p_{SFED}) \\times E[C_{rescue\\_branch}]$\n  $E[C_{SFED}] = (\\$400 + \\$1200 + 0 \\times \\$0) + (0.46) \\times \\$10810$\n  $E[C_{SFED}] = (\\$1600) + \\$4972.60 = \\$6572.60$.\n\n**Conclusion:**\nAll three initial therapy strategies meet the minimum remission probability constraint. We compare their expected total costs:\n- PPI Strategy: $\\$7672.80$\n- STC Strategy: $\\$5638$\n- SFED Strategy: $\\$6572.60$\n\nThe strategy with the minimal expected total cost is the one starting with the swallowed topical corticosteroid (STC). The minimal expected total cost is $\\$5638$. Rounding to four significant figures gives $5638$.",
            "answer": "$$\n\\boxed{5638}\n$$"
        }
    ]
}